Attenuation of Abnormal Scarring Using Spherical Nucleic Acids Targeting Transforming Growth Factor Beta 1

Area of Science:

• Biotechnology
• Dermatology
• Molecular Biology

Background:

• Abnormal scarring results from dysregulated wound healing, lacking effective noninvasive treatments.
• Spherical nucleic acids (SNAs) can penetrate skin and modulate gene expression.
• Transforming growth factor beta 1 (TGF-β1) is implicated in scar formation.

Purpose of the Study:

• To investigate gold-core SNAs (AuSNAs) and liposome-core SNAs (LSNAs) as topical therapies for scarring.
• To assess the ability of SNAs targeting TGF-β1 to downregulate its expression and improve scar characteristics.
• To evaluate the potential of SNAs for treating gene expression-driven skin disorders.

Main Methods:

• Synthesized AuSNAs and LSNAs carrying antisense oligonucleotides against TGF-β1.
• Tested SNA efficacy in vitro on hypertrophic and keloid scar fibroblasts.
• Administered topical AuSNAs and LSNAs in vivo and evaluated scar histology and TGF-β1 protein levels.

Main Results:

• Both AuSNAs and LSNAs significantly downregulated TGF-β1 protein expression in scar fibroblasts in vitro.
• Topical application of AuSNAs and LSNAs reduced TGF-β1 protein levels in vivo.
• SNAs improved scar histology, indicated by a reduced scar elevation index.

Conclusions:

• SNAs targeting TGF-β1 show promise as a topical therapy for abnormal scarring.
• These findings highlight the potential of SNAs for localized, self-managed treatment of skin conditions.
• SNAs represent a novel approach for managing skin diseases driven by elevated gene expression.